Enhancing Drug Bioavailability for Parkinson's Disease: The Promise of Chitosan Delivery Mechanisms.

Shaikh, MAJ; Kumar, G; Bagiyal, P; Gupta, S; Singh, SK; Pillappan, R; Chellappan, DK; Prasher, P; Jakhmola, V; Singh, TG; Dureja, H; Singh, SK; Dua, K

Enhancing Drug Bioavailability for Parkinson's Disease: The Promise of Chitosan Delivery Mechanisms.

Shaikh, MAJ Kumar, G Bagiyal, P Gupta, S Singh, SK Pillappan, R Chellappan, DK Prasher, P Jakhmola, V Singh, TG Dureja, H Singh, SK Dua, K

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Ann Pharm Fr, 2024, pp. S0003-4509(24)00107-X
Issue Date:: 2024-07-30

Closed Access

	Filename	Description	Size
	Chitosan_Parkinson.pdf	Published version	3.81 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shaikh, MAJ
dc.contributor.author	Kumar, G
dc.contributor.author	Bagiyal, P
dc.contributor.author	Gupta, S
dc.contributor.author	Singh, SK
dc.contributor.author	Pillappan, R
dc.contributor.author	Chellappan, DK
dc.contributor.author	Prasher, P
dc.contributor.author	Jakhmola, V
dc.contributor.author	Singh, TG
dc.contributor.author	Dureja, H
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2024-08-24T15:35:44Z
dc.date.available	2024-07-25
dc.date.available	2024-08-24T15:35:44Z
dc.date.issued	2024-07-30
dc.identifier.citation	Ann Pharm Fr, 2024, pp. S0003-4509(24)00107-X
dc.identifier.issn	0003-4509
dc.identifier.uri	http://hdl.handle.net/10453/180553
dc.description.abstract	Parkinson's disease (PD) is a widely seen neurodegenerative condition recognized by misfolded α-synuclein (αSyn) protein, a prominent indicator for PD and other synucleinopathies. Motor symptoms like stiffness, akinesia, rest tremors, and postural instability coexist with nonmotor symptoms that differ from person to person in the development of PD. These symptoms arise from a progressive loss of synapses and neurons, leading to a widespread degenerative process in multiple organs. Implementing medical and surgical interventions, such as deep brain stimulation, has enhanced individuals' overall well-being and long-term survival with PD. It should be mentioned that these treatments cannot stop the condition from getting worse. The complicated structure of the brain and the existence of a semi-permeable barrier, commonly known as the BBB, have traditionally made medication delivery for the treatment of PD a challenging endeavor. The drug's low lipophilic nature, enormous size, and peculiarity for various ATP-dependent transport mechanisms hinder its ability to enter brain cells. This article delves into the potential of drug delivery systems based on chitosan (CS) to treat PD.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Ann Pharm Fr
dc.relation.isbasedon	10.1016/j.pharma.2024.07.008
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.title	Enhancing Drug Bioavailability for Parkinson's Disease: The Promise of Chitosan Delivery Mechanisms.
dc.type	Journal Article
utslib.location.activity	France
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/All Manual Groups
pubs.organisational-group	University of Technology Sydney/All Manual Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/All Manual Groups/Centre for Inflammation (CFI)/Associate Member
utslib.copyright.status	closed_access	*
dc.date.updated	2024-08-24T15:35:41Z
pubs.publication-status	Published online

Abstract:

Parkinson's disease (PD) is a widely seen neurodegenerative condition recognized by misfolded α-synuclein (αSyn) protein, a prominent indicator for PD and other synucleinopathies. Motor symptoms like stiffness, akinesia, rest tremors, and postural instability coexist with nonmotor symptoms that differ from person to person in the development of PD. These symptoms arise from a progressive loss of synapses and neurons, leading to a widespread degenerative process in multiple organs. Implementing medical and surgical interventions, such as deep brain stimulation, has enhanced individuals' overall well-being and long-term survival with PD. It should be mentioned that these treatments cannot stop the condition from getting worse. The complicated structure of the brain and the existence of a semi-permeable barrier, commonly known as the BBB, have traditionally made medication delivery for the treatment of PD a challenging endeavor. The drug's low lipophilic nature, enormous size, and peculiarity for various ATP-dependent transport mechanisms hinder its ability to enter brain cells. This article delves into the potential of drug delivery systems based on chitosan (CS) to treat PD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/180553